- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: Controversy surrounding the Sputnik V vaccine. (Pubmed Central) - Nov 7, 2021 The Sputnik V COVID-19 vaccine is a member of the so-called vector vaccines and uses two different vectors (Ad26 priming and Ad5 boost) to reduce the risk of a reduction in the effectiveness of the vaccination...However, it is imperative to document the efficacy and safety of the Sputnik V vaccine in individuals with high pre-existing anti-Ad26 and Ad5-neutralizing antibody titres and in those under the age of 18 or older than 60 years and be certain that Sputnik V does not cause the rare development of immune thrombotic thrombocytopenia. It is hoped that the now widespread use of this vaccine will generate a large pragmatic real-world study with data accessible to anyone interested in verifying them.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Long Term Immune Response Produced by the SputnikV Vaccine. (Pubmed Central) - Nov 4, 2021 This breadth of reactivity was still evident 90 days after the first dose of the vaccine, showing that the vaccine has induced a prolonged response. As evidenced by the activation of T cells, cellular immunity strongly suggests the high potency of the SputnikV vaccine against SARS-CoV-2 infection.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
BIOMARKERS OF INFLAMMATION AND IMMUNE REGULATION IN COVID-19 PATIENTS AND COVID 19 VACCINATED INDIVIDUALS (Hall B (1st Floor); Monitor 10) - Nov 2, 2021 - Abstract #ACAAI2021ACAAI_937; Methods 20 patients who had COVID-19 infection (10 men and 10 women, age 37.6±17.0 years, 124.9±27.5 days after the first symptoms) and 22 patients who were vaccinated with the COVID 19 vaccine Sputnik-V (8 men and 14 women, age 53.3±12.8 years, 38.5±2.6 days after the first vaccination) were assessed...There was also a decrease in the concentration of presepsin, LBP and an increase in procalcitonin in the serum of Sputnik-V vaccinated individuals compared with those who had had the COVID 19 infection (p <0.05). Conclusions COVID 19 infection and COVID 19 vaccination both induce immune changes including immunoregulatory and inflammatory biomarker changes with differences seen between COVID 19 vaccinated and COVID 19 infected patients.
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Clinical: My father is 75 y.o. He took two shots of Covishield (Astrazeneca). First shot in March, Second in April. Which booster dose should he take, Covishield, covaxin or Sputnik V ? (these are the only vaccines available in India). (Twitter) - Oct 22, 2021
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Clinical, Journal: The social demographic aspects of vaccination of population of Russia in the context of COVID-19 pandemic (Pubmed Central) - Oct 22, 2021 Also, significant increase of percentage of vaccinated population can be achieved if clearly defined requirements for availability of COVID-19 vaccination would be adopted on the international level. Actually, this is key condition for restoring international mobility and removing restrictions in national economies.
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Clinical, Journal: Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report. (Pubmed Central) - Sep 29, 2021 For all vaccines, antibody levels were higher in individuals with past COVID-19 than in naïve individuals. A total of twelve new infections occurred within the first 3 months post-vaccination, eight after the first dose of BNT-162b2 and ChAdOx1-S (one each) and BBIBP-CorV (six), and four after full vaccination with BBIBP-CorV, but none required hospitalization.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Enrollment closed, Trial completion date, Trial primary completion date: Sputnik-HD: Immune Response in Dialysis Patients Vaccinated Against COVID-19 (clinicaltrials.gov) - Sep 27, 2021 P=N/A, N=42, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Jan 2022 | Trial primary completion date: Sep 2021 --> Jan 2022
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
[VIRTUAL] Safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2384; COVID-19 vaccines seem to be safe for pwMS from Latin America. No major safety signals appeared in this patient-reported study.
|